Skip to content
10-Q

Quarterly Report

10x Genomics, Inc. TXG

0001628280-26-032388

← back to feed
Filed
May 8, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Diluted Q1 2026 · Mar 31, 2026 128.29M sh
Shares Diluted Q1 2026 · Mar 31, 2025 122.61M sh
Capex Q1 2026 · Mar 31, 2026 $1.6M
Capex Q1 2026 · Mar 31, 2025 $1.89M
Operating Cash Flow Q1 2026 · Mar 31, 2026 $26.12M
Operating Cash Flow Q1 2026 · Mar 31, 2025 $34.35M
Stockholders Equity Q1 2026 · Mar 31, 2026 $814.32M
Stockholders Equity Q1 2026 · Dec 31, 2025 $796.33M
Stockholders Equity Q1 2026 · Mar 31, 2025 $706.9M
Stockholders Equity Q1 2026 · Dec 31, 2024 $710.13M
Current Liabilities Q1 2026 · Mar 31, 2026 $113.6M
Current Liabilities Q1 2026 · Dec 31, 2025 $153.45M
Total Liabilities Q1 2026 · Mar 31, 2026 $201.44M
Total Liabilities Q1 2026 · Dec 31, 2025 $245.04M
Current Assets Q1 2026 · Mar 31, 2026 $669.73M
Current Assets Q1 2026 · Dec 31, 2025 $684.45M
Total Assets Q1 2026 · Mar 31, 2026 $1.02B
Total Assets Q1 2026 · Dec 31, 2025 $1.04B
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.10
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.28
Eps Basic Q1 2026 · Mar 31, 2026 −$0.10
Eps Basic Q1 2026 · Mar 31, 2025 −$0.28
Sga Expense Q1 2026 · Mar 31, 2026 $66.38M
Sga Expense Q1 2026 · Mar 31, 2025 $89.73M
Net Income Q1 2026 · Mar 31, 2026 −$13.47M
Net Income Q1 2026 · Mar 31, 2025 −$34.36M
Operating Income Q1 2026 · Mar 31, 2026 −$17.05M
Operating Income Q1 2026 · Mar 31, 2025 −$39.33M
Gross Profit Q1 2026 · Mar 31, 2026 $106.18M
Gross Profit Q1 2026 · Mar 31, 2025 $105.45M
Cost Of Revenue Q1 2026 · Mar 31, 2026 $44.67M
Cost Of Revenue Q1 2026 · Mar 31, 2025 $49.44M
Revenue Q1 2026 · Mar 31, 2026 $150.84M
Revenue Q1 2026 · Mar 31, 2025 $154.88M